OncoSignatur Breast is an under-development breast-cancer prognostic test kit for local hospitals or clinical laboratories using standard qPCR machines.
View competitorsFounded with a mission to make precision diagnostics more accessible, Signatur Biosciences focuses on developing affordable and rapid blood tests for complex diseases, starting with breast cancer prognosis. Their innovative molecular technology enables local hospital labs to perform diagnostics that traditionally required complex centralized facilities, significantly reducing turnaround time and costs. By leveraging widely accessible PCR equipment, Signatur Biosciences aims to democratize high-quality healthcare diagnostics globally.
Notable affiliated individuals and investors have supported Signatur Biosciences in its journey to revolutionize medical diagnostics. The company has achieved significant milestones, including the development of diagnostic kits that reduce the time for breast cancer prognosis from over three weeks to just a few days at half the traditional cost. This breakthrough has had a profound impact on patient care, enabling quicker and more affordable access to life-saving information.
As of Oct 1, 2022, Signatur Biosciences has disclosed funding of $500k (USD).

Digistain
digistain.co.uk

Prompt Diagnostics
prompt-dx.com

Harbinger Health

Probius
probius.bio

BloodQ
bloodq.com

Valtari Bio

Aperture Bio
aperture.bio

Precipio
precipiodx.com

Nanopath
nanopathdx.com

Metfora
metfora.com

MeCo Diagnostics

Salish Bioscience

Babson Diagnostics
babsondx.com

Epinoma
epinoma.com

FYR Diagnostics
fyrdiagnostics.com

Cadex Genomics
cadexgenomics.com

Summit Biolabs
summitbiolabs.com

Hawkeye Bio
hawkeyebio.com
Predictive Biosciences

Isabl
isabl.io